U.S. Markets close in 6 hrs 11 mins

Marina Biotech, Inc. (MRNA)


Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.38-0.01 (-2.56%)
As of 2:21PM EDT. Market open.
People also watch
RXIIPARDCYCCOPXAGNVC
Full screen
Previous Close0.39
Open0.00
Bid0.00 x
Ask0.00 x
Day's Range0.00 - 0.00
52 Week Range
Volume12
Avg. Volume59,315
Market Cap36.92M
Beta3.29
PE Ratio (TTM)-12.67
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Marina Biotech, Inc. :MRNA-US: Earnings Analysis: Q3, 2016 By the Numbers : November 23, 2016
    Capital Cube7 months ago

    Marina Biotech, Inc. :MRNA-US: Earnings Analysis: Q3, 2016 By the Numbers : November 23, 2016

    Categories: Yahoo Finance Get free summary analysis Marina Biotech, Inc. reports financial results for the quarter ended September 30, 2016. We analyze the earnings along side the following peers of Marina Biotech, Inc. – Regulus Therapeutics Inc., Merck & Co., Inc., Athersys, Inc., Alnylam Pharmaceuticals, Inc, Johnson & Johnson, Monsanto Company, Novartis AG Sponsored ADR, Flamel Technologies SA ... Read more (Read more...)

  • Marina Biotech, Inc. Earnings Q3, 2015
    Capital Cube2 years ago

    Marina Biotech, Inc. Earnings Q3, 2015

    Click here to see latest analysisMarina Biotech, Inc. reports financial results for the quarter ended September 30, 2015.We analyze the earnings along side the following peers of Marina Biotech, Inc. – Regulus Therapeutics Inc., Merck & Co., Inc., Athersys, Inc., Alnylam Pharmaceuticals, Inc, Johnson & Johnson, Monsanto Company, Novartis AG Sponsored ADR, Flamel Technologies SA […] (Read more...) The post Marina Biotech, Inc. Earnings Q3, 2015 appeared first on CapitalCube.

  • Marina Biotech, Inc. – Value Analysis (US OTC:MRNA) : November 3, 2015
    Capital Cube2 years ago

    Marina Biotech, Inc. – Value Analysis (US OTC:MRNA) : November 3, 2015

    Capitalcube gives Marina Biotech, Inc. a score of 38.Our analysis is based on comparing Marina Biotech, Inc. with the following peers – Regulus Therapeutics Inc., Merck & Co., Inc., Athersys, Inc., Alnylam Pharmaceuticals, Inc, Johnson & Johnson, Monsanto Company, Arrowhead Research Corporation, Novartis AG Sponsored ADR, Flamel Technologies SA Sponsored ADR and Dicerna Pharmaceuticals, Inc. […] (Read more...) The post Marina Biotech, Inc. – Value Analysis (US OTC:MRNA) : November 3, 2015 appeared first on CapitalCube.